Compare the Best Pharmacovigilance Vendors

Who this guide is for

This guide is for biotech sponsors choosing an outsourced safety partner for clinical development: typically a clinical operations or drug safety lead without an in-house safety department, preparing for a first-in-human study, a pivotal Phase III programme or the move to a marketed medicine. If you are looking for the best pharmacovigilance vendors for biotech, the real decision is narrower than any list. Who will process and assess your serious adverse events, who signs off causality and expectedness, and whose validated database will hold the record an inspector reads? The vendor cards above show which vendors in our directory sit in this category and the profile fields we hold for each. They cannot tell you whether a vendor’s case team, gateways or physicians suit your molecule. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score.

What a pharmacovigilance vendor does — and when you need one

In clinical development, a pharmacovigilance vendor runs some or all of the sponsor’s safety obligations: serious adverse event (SAE) intake from sites, case entry in a safety database, MedDRA coding, medical review of seriousness, causality and expectedness, expedited reporting of suspected unexpected serious adverse reactions (SUSARs) to regulators, ethics committees and investigators, SAE reconciliation with the clinical database, the Development Safety Update Report (DSUR) and signal detection. Many also host the database and, after approval, run vigilance for the marketing authorisation holder.

The boundaries matter. A full-service CRO may bundle safety with monitoring and data management; a specialist safety vendor concentrates on the case and the submission; a safety technology vendor supplies software or automation, not necessarily the people. An independent data monitoring committee reviews unblinded aggregate data and advises the sponsor, but does not process cases.

Under ICH E6(R3) the sponsor can delegate safety tasks but keeps ultimate responsibility for them. Typical triggers for outsourcing are a first clinical trial application, expansion into regions that need new regulator connections, a pivotal study whose SUSAR flow will outgrow a lone in-house physician, and the approach to marketing authorisation, when a qualified person responsible for pharmacovigilance (QPPV) and a pharmacovigilance system master file become mandatory.

How to evaluate a pharmacovigilance vendor

Expedited reporting against ICH E2A

ICH E2A sets the clock: fatal or life-threatening SUSARs are reported no later than seven calendar days after the sponsor first has the minimum information for a valid case, with a follow-up report within a further eight days; all other SUSARs within fifteen calendar days. Day zero starts when anyone acting for the sponsor, including its vendor, receives that information. Ask how late cases are measured, how root cause and CAPA are handled, and how weekends and public holidays are covered.

SUSAR handling and unblinding

Ask who assesses expectedness, against which reference safety information, and how changes to that information in the investigator’s brochure are version-controlled. In blinded studies the treatment code is normally broken for the SUSAR case only, by people outside the study team. Request a redacted walk-through from receipt to submission and investigator notification.

E2B(R3) gateways and regulator connections

Individual case safety reports travel in ICH E2B(R3) format. Under Regulation (EU) No 536/2014, SUSARs go to the clinical trials module of EudraVigilance; UK trials report electronically to the MHRA; US investigational new drug safety reports go to the FDA, which accepts E2B(R3). Confirm which connections are live and tested today, whose registrations they run under (normally the sponsor’s, with the vendor acting on its behalf), and how acknowledgements and rejections are monitored.

Safety database validation

Whether the vendor hosts a commercial safety system or its own platform, ask for the validation package and how the system meets 21 CFR Part 11 and EU GMP Annex 11 expectations for audit trails, electronic signatures and access control. Clarify who owns the data, how it is exported at contract end, and how MedDRA and WHODrug upgrades are managed mid-study.

Medical review and physician depth

The physician layer separates a data-entry service from a safety partner. Ask who performs medical review, what experience they have in your indication, and how disagreement with an investigator is recorded: the sponsor may add its own opinion but should not downgrade the investigator’s causality assessment for reporting purposes. Ask whether a safety physician can sit on your safety management team.

Aggregate reporting and signals

Ask for an anonymised DSUR written to ICH E2F, how its reporting period is anchored to the development international birth date, and how cumulative data feed signal detection and updates to the reference safety information. In the EU the DSUR serves as the annual safety report submitted through CTIS.

UK and EU regulatory footprint

If your search began with "pharmacovigilance CRO UK", test UK depth separately from EU depth. Since leaving the EU, the UK has run its own regulator systems through the MHRA and has modernised its clinical trials regulations. For marketed products the MHRA requires a QPPV, a UK-based national contact for pharmacovigilance where that QPPV does not reside in the UK, and a pharmacovigilance system master file; the EU QPPV must reside and operate in the EU or EEA. Ask which of these roles the vendor provides, and from where.

Readiness for post-marketing

Biotechs often outgrow a trial-only safety vendor at approval. Ask whether the vendor can migrate case history into a post-marketing system, run spontaneous and literature case intake, author periodic benefit-risk evaluation reports to ICH E2C(R2), and support the QPPV and master file. A planned transition costs far less than a vendor change in the middle of a launch.

Pharmacovigilance vendors at a glance

The table below sets the vendors profiled on this page side by side on the fields we hold: vendor type, service model, geography, headquarters, study phases, therapeutic focus and trial scale. Use it to separate full-service CROs that include safety from specialist pharmacovigilance providers before reading the profiles.

Read honestly, these records are more alike than different. Every vendor listed covers Phase I to Phase IV with a global footprint. Allucent is the only specialist CRO here, combining clinical, regulatory and pharmacovigilance services and listing rare disease alongside generalist work; the rest are typed as pharmacovigilance and safety providers with generalist coverage. What will decide your shortlist (gateway connections, physician depth, database model, UK presence) is not a table field, so it belongs in your RFP. All fields come from each vendor’s Clinical Vendor Compare profile.

Vendor profiles

Allucent

Allucent is a specialist CRO whose service model combines clinical, regulatory and pharmacovigilance work, with global coverage, a United States headquarters, Phase I to Phase IV, and generalist plus rare disease focus, sized for mid-size programmes and emerging biotech portfolios. Its best fit is sponsors seeking a clinical CRO with global coverage, and its stated strength is full-service support from early stage to post-approval for biotech and small-to-mid pharma. Where to probe: whether safety runs through a dedicated pharmacovigilance team with its own validated database and gateways.

3R Pharma Consulting

3R Pharma Consulting is profiled as a pharmacovigilance and safety provider with a global footprint, Phase I to Phase IV coverage, generalist therapeutic focus and focused global studies. Its best fit is sponsors seeking specialist outsourced pharmacovigilance support, with boutique flexibility and specialist focus as stated strengths. Where to probe: the profile notes it is smaller in scale than major providers, so test surge capacity for a cluster of SUSARs, out-of-hours intake, and medical review cover when a named physician is away.

APCER Life Sciences

APCER Life Sciences is typed as a pharmacovigilance and safety provider with global reach, Phase I to Phase IV coverage and generalist focus across focused global studies. The record positions it for programmes needing safety case processing, vigilance or medical safety support, and lists safety compliance, case processing and reporting discipline as strengths. Where to probe: its profile notes it requires tight handoffs with clinical operations and medical teams, so ask for the proposed SAE intake route from sites, the reconciliation schedule with your EDC provider and the escalation path to your medical monitor.

Auriga Research Pharmacovigilance

Auriga Research Pharmacovigilance is profiled as a pharmacovigilance and safety provider with a global footprint, Phase I to Phase IV coverage and generalist focus for focused global studies. Its stated best fit is sponsors wanting CRO-adjacent safety support with cost leverage, and its strengths are operational flexibility and a broader service mix. Where to probe: the record notes it may require careful scope design for complex global programmes, so list every country, regulator connection and distribution obligation in the statement of work rather than leaving any assumed.

Biologit

Biologit is typed as a pharmacovigilance and safety provider with global coverage, Phase I to Phase IV, generalist focus and focused global studies. Its best fit is teams modernising pharmacovigilance workflows with automation, and its strengths are an automation angle and focused safety technology. Where to probe: the profile states it is not a broad case-processing services outsourcer, so clarify whether you are buying technology, a service or both, and who carries case processing, medical review and expedited submission if its scope stops at the tooling.

Clinigen Pharmacovigilance

Clinigen Pharmacovigilance appears in the directory as a pharmacovigilance and safety provider operating globally across Phase I to Phase IV, with generalist focus and focused global studies. Its record points to programmes that need safety case processing, vigilance or medical safety support, with safety compliance, case processing and reporting discipline as strengths. Where to probe: the profile notes it needs tight handoffs with clinical operations and medical teams, so ask how the safety management plan splits duties between the vendor, your CRO and your medical monitor.

DDReg Pharma Safety Services

DDReg Pharma Safety Services is recorded as a pharmacovigilance and safety provider with global coverage, Phase I to Phase IV and generalist focus for focused global studies. Its best fit is smaller sponsors needing specialist regulatory and pharmacovigilance support, with hands-on consultancy and regulatory overlap as stated strengths. Where to probe: the profile says it is not built for very high-volume enterprise operations, so test its plan if a pivotal study or launch sharply increases case volume.

Drug Safety Solutions

Drug Safety Solutions is profiled as a pharmacovigilance and safety provider with global coverage, Phase I to Phase IV and generalist focus across focused global studies. Its best fit is sponsors needing trial safety operations and post-market vigilance support, which makes it relevant to biotechs planning the step to a marketed product. Stated strengths are safety process rigour, reporting and global vigilance support. Where to probe: the record indicates it does not suit teams seeking only core trial operations, so ask how it would share SAE intake and reconciliation with your clinical CRO.

DSRU

DSRU’s record types it as a pharmacovigilance and safety provider with global reach, Phase I to Phase IV coverage, generalist focus and focused global studies. It is positioned for programmes needing safety case processing, vigilance or medical safety support, with safety compliance, case processing and reporting discipline as listed strengths. Where to probe: the profile notes it requires tight handoffs with clinical operations and medical teams, so ask for a sample safety management plan and the turnaround it expects from sites and your medical monitor.

ELIQUENT Drug Safety

ELIQUENT Drug Safety is listed as a pharmacovigilance and safety provider with global coverage, Phase I to Phase IV and generalist focus for focused global studies. Its record positions it for programmes needing vigilance, safety operations or safety platform support, with safety compliance, case processing and reporting discipline as strengths. Where to probe: beyond the tight clinical and medical handoffs its profile flags, ask whether platform support includes validated database hosting, who controls configuration, and how your data would be exported in E2B(R3) format.

Engagement and pricing models

Biotechs buy clinical pharmacovigilance in a few recognisable ways. Bundled into a full-service CRO contract, safety is convenient but can be hard to separate out at approval. Bought standalone from a specialist, it is usually unit-based: a fee per case processed, per expedited submission and per aggregate report, plus recurring fees for database hosting, the safety physician and project management. Larger programmes sometimes move to FSP or FTE-based models that buy dedicated capacity, and hybrid models pair a fixed retainer with unit fees above an agreed volume.

Cost drivers are predictable: case volume and complexity, the number of countries and regulator connections, translation, depth of medical review, database licensing and validation, and set-up work such as the safety management plan and gateway testing. Ask each vendor to price your own SAE and SUSAR forecast rather than a generic scenario. A low per-case fee with expensive change orders can cost more than a higher all-in rate, so get change-order triggers in writing and price the exit, including data migration, before you sign.

Questions to put in your RFP

• How do you define and record day zero for a case first received by a site, a CRO monitor or your intake mailbox?
• Which E2B(R3) connections are live and tested today for EudraVigilance, the MHRA and the FDA, and whose registrations do they use?
• Can you walk us through a redacted SUSAR from receipt to submission, including unblinding and investigator notification?
• How do you control a mid-study change to the reference safety information?
• Who performs medical review, with what qualifications, and how do you document disagreement with an investigator’s causality assessment?
• Which safety database do you propose, who owns the data, and may we see its validation summary?
• How often do you reconcile SAEs with the clinical database, and who closes discrepancies?
• How do you measure late expedited reports, and what CAPA followed your most recent one?
• Can you write our DSUR to ICH E2F and support its submission as the EU annual safety report?
• At marketing authorisation, can you provide a QPPV, master file maintenance and post-marketing intake for the UK and EU?
• Which activities would you subcontract, and to whom?

Due-diligence red flags

• Day zero defined as when the vendor, rather than anyone acting for the sponsor, first received the case.
• No live, tested regulator connection for a region where you will open sites.
• Medical review with no physician sign-off on seriousness, causality and expectedness.
• A safety database with no current validation package, audit-trail review or change control.
• Unblinding procedures that could expose treatment allocation to the study team.
• SAE reconciliation left undefined or described as "as needed".
• Reluctance to accept sponsor audits or summarise past inspection outcomes.
• Opaque subcontracting of case intake, coding or medical review.
• No exit plan, or data export only in a proprietary format.
• An offer to provide a QPPV with no clarity on where that person resides and operates.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter pharmacovigilance and safety providers by phase, geography and service model. Put your shortlist side by side in compare, checking each profile against the criteria and red flags above. When you are ready to approach vendors, the sponsor RFP page helps you build a structured request around the questions in this guide, so every response can be read against the same yardstick. If you have worked with any of these vendors on a trial, please write a review: your experience directly helps the next biotech facing the same decision.